Search
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Amiloxate
go.drugbank.com/drugs/DB11207ApprovedAmiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m . It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid...
Domperidone
go.drugbank.com/drugs/DB01184ApprovedInvestigationalVet approvedA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...
Bromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuro...
Candesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalCandesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents
Boron
go.drugbank.com/drugs/DB11203ApprovedInvestigationalNatural boron exists in 2 stable isotopes however pure boron is hard to prepare due to contamination by different elements.
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence